The export to the Translational Psychedelic Research Program at UCSF represents an important step in advancing clinical research on natural psilocybin
Vancouver, British Columbia, August 26, 2021 – Filament Health Corp. NEO:FH. (“Filament” or the “Company”), a leading exclusively-natural psychedelic drug development company, today announced that it has completed a shipment of Good Manufacturing Practices (GMP) compliant natural psilocybin into the United States through its wholly owned subsidiary, Psilo Scientific Ltd.. This export is believed to be the first of its kind, and was shipped from Filament’s Vancouver facility to the University of California San Francisco’s (UCSF) Translational Psychedelic Research Program (TrPR), in connection with an anticipated phase 1 FDA trial and ongoing clinical trial partnership.
“This is an important milestone for Filament as we have demonstrated our ability to transport a controlled substance – in this case standardized psilocybin extract – for our own research purposes. It also opens the door to working with other international licensed research sites.” said Benjamin Lightburn, CEO of Filament Health. “We believe that this is the first transborder shipment of naturally-extracted GMP psilocybin – an achievement which validates our regulatory team’s work and affirms our ability to work closely with government agencies in Canada and abroad.”
The shipment consists of capsules containing Filament’s proprietary formulation which is precisely standardized to include 25 milligrams of natural psilocybin. The capsules, which leverage Filament’s intellectual property portfolio, were manufactured in-house in, by Psilo Scientific accordance with its Health Canada Dealer’s License. The shipment was delivered to TrPR via a Health Canada export permit and US Drug Enforcement Administration import permit.
This development comes soon after Filament was issued the first patent for the extraction and standardization of natural psilocybin on August 3rd, and its wholly owned subsidiary, Psilo Scientific, received an amendment to its Health Canada Dealer’s License, allowing for work with all natural psychedelics, on July 29th.
ABOUT FILAMENT HEALTH
Filament is an exclusively-natural psychedelic drug discovery and extraction technology company. Its mission is to see safe, approved, natural psychedelics in the hands of everyone who needs them as soon as possible. Filament believes measurable and efficacious medicines will be a catalyst to addressing many of the world’s mental health problems and that natural psychedelics provide an optimal option for widespread adoption of these substances. Filament engages in natural extraction technology commercialization, utilizing its intellectual property portfolio and Psilo Scientific’s in-house GMP facility, and Health Canada Dealer’s License for all natural psychedelics. Filament is headquartered in Vancouver, British Columbia and trades on Canada’s NEO Exchange (NEO:FH).
Learn more at www.filament.health and on Twitter, Instagram and LinkedIn.
MEDIA CONTACT
Anna Cordon, Director of Communications
778.245.9067
anna@filament.health
INVESTOR RELATIONS CONTACT
FORWARD LOOKING INFORMATION
Certain statements and information contained herein may constitute “forward-looking statements”and “forward-looking information,” respectively, under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “should”, “believe”, “intends”, “forecast”, “plans”, “guidance” and similar expressions are intended to identify forward-looking statements or information. The forward-looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward-looking statements. The forward-looking statements discussed in this press release may include, but are not limited to, information concerning Filament’s and TrPR’s ability to conduct clinical trials; the results of the partnership; the nature, timing, and possible success of Filament’s leading drug candidates and the impact and accessibility of psychedelic treatments. Forward-looking statements regarding the Company are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Filament will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
.jpg)
